-
2025 HDBuzz Prize: ACTing on HD: Exploring Acceptance and Commitment Therapy to Improve Mental Health in People with Huntington’s Disease and Their Caregiver
Latest News
-
2025 HDBuzz Prize: Calm Before the Storm: Early Clues of Huntington’s Disease Found in Brainwaves
We’re proud to announce Eva Woods as a 2025 HDBuzz Prize winner! Scientists spotted small brainwave changes in people with HD before symptoms begin. These early electrical “whispers” of HD could help track effects years before diagnosis.
-
uniQure gets the green light to resume testing HD gene therapy
Following a 3-month pause in enrollment due to concerns about side effects, uniQure shared the good news that their trial of the HD gene therapy AMT-130 will continue as planned, with new safety measures in place.
-
Update on the PTC Therapeutics PIVOT-HD Trial
Last week, PTC Therapeutics released a statement sharing that recruitment of participants into the US arm of the PIVOT-HD trial has been paused. In this article, we will lay out exactly what is known and what this announcement means.
-
Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials
Two companies developing medicines for Huntington’s disease announced news about their huntingtin-lowering drugs. Let’s talk about the history and the caveats surrounding these hopeful pieces of news.
-
Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps
Scientists have used powerful microscopes to look at sticky fragments of the Huntington’s disease protein, shedding light on these structures which are thought to drive the disease
-
Hereditary Disease Foundation (HDF) conference 2022 – Day 4
Read updates from clinical trials and scientific research on Huntington’s disease from Day 4 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022
-
Hereditary Disease Foundation (HDF) conference 2022 – Day 3
Read updates from clinical trials and scientific research on Huntington’s disease from Day 3 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022
-
Hereditary Disease Foundation (HDF) conference 2022 – Day 2
Read updates from clinical trials and scientific research on Huntington’s disease from Day 2 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022
-
Hereditary Disease Foundation (HDF) conference 2022 – Day 1
Read updates from clinical trials and scientific research on Huntington’s disease from Day 1 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022
-
Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
After receiving a high dose of uniQure’s gene therapy for Huntington’s disease, a few patients experienced serious side effects, but are now recovering. HDBuzz explores what this means for the experimental huntingtin-lowering drug, AMT-130.
-
Sad news from Novartis: dosing suspended in VIBRANT-HD trial of branaplam
HDBuzz is saddened to share the news that the VIBRANT-HD trial of the oral huntingtin-lowering drug, branaplam, has been temporarily suspended for the safety of participants.